|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan
Business Insights, April 2005, Pages: 240
Maximizing prices and securing reimbursement status for a product is increasing in importance, as pharmaceutical companies seek to ensure that they achieve a high return on investment from current and future drugs in light of a sustained R&D productivity shortfall and a wave of impending blockbuster patent expiries.
Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan, is a report which will help you create an effective pricing policy, in the midst of continued regulatory uncertainty, stagnant R&D and the continued cost-containment efforts of healthcare payors. This report will provide detailed analysis of the key issues and market environments making up the pricing landscape, and enable you to conduct pricing and reimbursement evaluations for products throughout the development lifecycle.
Gain a detailed understanding a drug's potential price profile and optimize future returns by including these assessments in portfolio evaluations and lifecycle planning, with the help of this report.
Key findings of the report
- Over the next five years, the most likely pricing scenario in Europe will see the impact of pharmacoeconomics, parallel trade and generic
substitution continue to increase gradually. The accession of 10 new countries to the EU will have a small, but negative, effect on prices
throughout the EU-15.
- Over the next five years, the most likely pricing scenario prevailing in Japan will involve a continuation of the current reimbursement reform led by biennial price-cutting. By weighting the cuts against generic
and 'me-too' products, innovative products can still continue to receive premium prices, while the overall drugs bill is reduced.
- To maximize return from drug development investment, companies need to ensure the evidence that demonstrates product value and
supports the case for reimbursement, is strongly and effectively communicated in the decision-making process.
- The pricing of a reformulation relative to other formulations, can be divisive in dictating the success of reformulation strategies. To achieve growth, manufacturers must often strike a balance between the premium pricing of reformulations and ensuring that pricing remains
competitive and does not restrict volume driven growth.
Key questions answered in this report
- What are the major issues currently impacting on pharmaceutical pricing?
- How will the key trends in pharmaceutical R&D productivity
and healthcare spend affect pharmaceutical pricing strategies?
- What impact will Medicare reform have on the US pricing of drugs for seniors?
- What are the current pricing regulations and associated issues in the major pharma markets including North America, Europe and Asia Pacific?
- How will EU accession impact on pricing, parallel imports and generic competition in EU's major market?
- What are the likely future developments in pricing in the major pharma markets including North America, Europe and Japan?
- What can be done to maximize returns through applying different pricing strategies across the drug lifecycle?
Top five reasons to order your copy today
1.) Plan an optimum pricing strategy using forecasts of different
pricing scenarios in major markets (including the US, Japan and
Europe).
2.) Compare and contrast different pricing and reimbursement environments in key markets including the US, Japan, France, Germany, Italy, Spain, the UK, Canada, Australia and China.
3.) Optimize return on investment across the drug lifecycle by understanding the implications of using different pricing strategies at
various stages in the product lifecycle.
4.) Measure the impact of health economics, parallel imports and generic substitution on pricing in major markets including the US,
Japan, France, Germany, Italy, Spain and the UK.
5.) Benchmark a variety of different case studies outlining the use of different pricing strategies by different companies, for different
drugs, in different pricing environments.
|
|
|
|
